Ivy Brain Tumor Center and its partner Sonalasense have announced positive initial results in a first-in-human Phase 0/1 clinical trial involving recurrent glioblastoma patients.
Sonalasense has developed a noninvasive sonodynamic therapy (SDT) that pairs low-intensity ultrasound with chemotherapeutic agents known as sonosensitizers. The therapy is noninvasive.
Data from the trial indicate that SDT swiftly causes targeted oxidative stress and cell death in human glioblastoma tissue. In addition, the therapy was well tolerated in the study.
Get the full story from our sister site, Drug Discovery & Development.